N/A
N=42
Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes
Type 1 Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT00727220 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Change in HgBA1c — 8.5; 8.7 percentage of glycosylated hemoglobin
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric · 1+ yrs
- Sex
- All
- Sponsor
- Indiana University
- Primary completion
- Apr 2003
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in HgBA1c |
8.5; 8.7 | — |
Summary
The purpose of the study is to examine glycemic and neuropsychological outcomes in very young children with Type I diabetes who are being started on insulin pumps and to compare their outcomes to children who are not utilizing insulin pumps. We propose to assess 40 children with IDDM under 5 years of age. 10 patients examined will be using multiple daily injections with basal glargine, 10 will be using NPH or Lente and rapid-acting insulin, and 20 will be examined prior to and 12 months after the implementation of insulin pump therapy. These subjects will be recruited and followed because they are currently undergoing treatment for Type 1 diabetes. Children will be recruited based upon the insulin regimen that they and their primary diabetes physician have chosen to utilize clinically. Insulin regimens will not be changed by the study team. Outcome measures will examine: glycemic outcomes (overall control, blood sugar variability), cognitive outcomes, parenting Stress, and changes in diet.
Eligibility Criteria
Inclusion Criteria
- Children with Type I diabetes:
- Children must be 5 years of age or less at the time of entry into the study.
- Children must have had a diagnosis of type I diabetes for at least 1 year at time of entry.
- Children must be receiving two or more insulin injections daily.
Exclusion Criteria
- Children will be excluded if they have additional medical problems requiring treatment with agents known to affect blood glucose such as steroids or L-asparaginase.
- Children must not have any other chronic illness in addition to diabetes.
Data sourced from ClinicalTrials.gov (NCT00727220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.